Advaxis submits special protocol assessment to FDA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Advaxis Inc. submitted a Special Protocol Assessment request to the FDA to initiate detailed design discussions for a phase III clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login